AU2016298951B2 - Compositions for the treatment of cataracts - Google Patents

Compositions for the treatment of cataracts Download PDF

Info

Publication number
AU2016298951B2
AU2016298951B2 AU2016298951A AU2016298951A AU2016298951B2 AU 2016298951 B2 AU2016298951 B2 AU 2016298951B2 AU 2016298951 A AU2016298951 A AU 2016298951A AU 2016298951 A AU2016298951 A AU 2016298951A AU 2016298951 B2 AU2016298951 B2 AU 2016298951B2
Authority
AU
Australia
Prior art keywords
composition
cholesten
steroid
cataracts
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016298951A
Other languages
English (en)
Other versions
AU2016298951A1 (en
Inventor
Sam L. Nguyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catacore Inc
Original Assignee
Catacore Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catacore Inc filed Critical Catacore Inc
Publication of AU2016298951A1 publication Critical patent/AU2016298951A1/en
Application granted granted Critical
Publication of AU2016298951B2 publication Critical patent/AU2016298951B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016298951A 2015-07-27 2016-07-27 Compositions for the treatment of cataracts Ceased AU2016298951B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562197477P 2015-07-27 2015-07-27
US62/197,477 2015-07-27
US201562202518P 2015-08-07 2015-08-07
US62/202,518 2015-08-07
US201562252120P 2015-11-06 2015-11-06
US62/252,120 2015-11-06
US201662295267P 2016-02-15 2016-02-15
US62/295,267 2016-02-15
PCT/US2016/044337 WO2017019808A1 (en) 2015-07-27 2016-07-27 Compositions for the treatment of cataracts

Publications (2)

Publication Number Publication Date
AU2016298951A1 AU2016298951A1 (en) 2018-02-22
AU2016298951B2 true AU2016298951B2 (en) 2019-07-04

Family

ID=56616065

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016298951A Ceased AU2016298951B2 (en) 2015-07-27 2016-07-27 Compositions for the treatment of cataracts

Country Status (7)

Country Link
US (2) US10398709B2 (enExample)
EP (1) EP3328389A1 (enExample)
JP (1) JP2018522070A (enExample)
CN (1) CN108472303A (enExample)
AU (1) AU2016298951B2 (enExample)
CA (1) CA2993196A1 (enExample)
WO (1) WO2017019808A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
EP3086793B1 (en) 2013-12-24 2022-05-11 Virginia Commonwealth University Use of oxygenated cholesterol sulfates (ocs) for the treatment of kidney dysfunction
CN108350021A (zh) * 2015-09-08 2018-07-31 视点医疗公司 用于治疗眼科疾病的化合物和制剂
KR102593667B1 (ko) 2016-08-02 2023-10-24 버지니아 커먼웰스 유니버시티 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물
CA3078680A1 (en) * 2017-11-17 2019-05-23 Mahmood Piraee Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders
WO2020003051A1 (en) * 2018-06-27 2020-01-02 Cellix Bio Private Limited Ophthalmic compositions and methods for the treatment of eye disorders
JP2022529363A (ja) * 2019-04-19 2022-06-21 バック・インスティテュート・フォー・リサーチ・オン・エイジング Ｃｒｙａｂ凝集阻害剤である２５－ヒドロキシコレステロール（２５ｈｃ）は新規の老化細胞除去剤である
MX2021009520A (es) * 2021-08-06 2023-02-07 Foodvica S A De C V Composicion oftalmica para el tratamiento de trastornos visuales.
JP7784525B2 (ja) * 2021-08-18 2025-12-11 コアンチョウ オキュサン オフサルミック バイオテクノロジー カンパニー リミテッド 薬物組成物、その調製方法及び応用
US20240374615A1 (en) * 2021-08-18 2024-11-14 Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. Application of steroid compound in preparation of drug for preventing and/or treating eye floaters
CN115737654B (zh) * 2021-09-03 2025-11-21 成都瑞沐生物医药科技有限公司 一种滴眼给药预防和/或治疗白内障的眼用制剂
EP4467144A4 (en) 2022-01-21 2026-01-21 Senju Usa Inc AQUEOUS LIQUID FORMULATION
AU2023411014A1 (en) * 2022-12-23 2025-08-07 Durect Corporation 25-hydroxy-cholest-5-en-3-sulfate choline, formulations thereof and methods for preparing, and medical uses of same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014015024A2 (en) * 2012-07-17 2014-01-23 Regents Of The University Of Michigan Non-surgical method of treatment for cataract
WO2016029199A1 (en) * 2014-08-22 2016-02-25 Kang Zhang Compositions and methods to treat vision disorders
WO2016029197A1 (en) * 2014-08-22 2016-02-25 Kang Zhang Compositions and methods to treat and/or prevent vision disorders of the lens of the eye

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US4192827A (en) 1974-06-27 1980-03-11 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers
US4136250A (en) 1977-07-20 1979-01-23 Ciba-Geigy Corporation Polysiloxane hydrogels
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US20020132758A1 (en) 2001-01-18 2002-09-19 Shell John W. Method for identifying compounds to treat medical pathologies associated with molecular crystallization
AU2002360489A1 (en) * 2001-12-07 2003-06-23 The Regents Of The University Of California Treatment for age-related macular degeneration
EP2890363A1 (en) 2012-08-31 2015-07-08 Bausch & Lomb Incorporated Ophthalmic compositions with omega-3 fatty acids
WO2015085121A1 (en) * 2013-12-05 2015-06-11 University Of Miami Compositions and methods for reducing intraocular pressure

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014015024A2 (en) * 2012-07-17 2014-01-23 Regents Of The University Of Michigan Non-surgical method of treatment for cataract
WO2016029199A1 (en) * 2014-08-22 2016-02-25 Kang Zhang Compositions and methods to treat vision disorders
WO2016029197A1 (en) * 2014-08-22 2016-02-25 Kang Zhang Compositions and methods to treat and/or prevent vision disorders of the lens of the eye

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHAO, L. et al. "Lanosterol reverses protein aggregation in cataracts" Nature (2015) vol. 523, no. 7562, pages 607-611, published online 22 July 2015 *

Also Published As

Publication number Publication date
CN108472303A (zh) 2018-08-31
EP3328389A1 (en) 2018-06-06
AU2016298951A1 (en) 2018-02-22
WO2017019808A1 (en) 2017-02-02
US20200016176A1 (en) 2020-01-16
CA2993196A1 (en) 2017-02-02
JP2018522070A (ja) 2018-08-09
US10398709B2 (en) 2019-09-03
US20170027961A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
AU2016298951B2 (en) Compositions for the treatment of cataracts
USRE50218E1 (en) Non-steroidal anti-inflammatory ophthalmic compositions
DK2403488T3 (en) Ophthalmic carrier having delayed release
US20070287749A1 (en) Bromfenac ophthalmic formulations and methods of use
US8372814B2 (en) Ophthalmic formulations and uses thereof
US20130165419A1 (en) Combination anti-inflammatory ophthalmic compositions
US9289396B2 (en) Collagen-based implants for sustained delivery of drugs
US20130217657A1 (en) Combination anti-inflammatory ophthalmic compositions
TW201642914A (zh) 用於治療眼部疾病及失調的裝置及方法
US8748402B2 (en) Ophthalmic formulations and uses thereof
WO2014160579A1 (en) Combination anti-inflammatory ophthalmic compositions
TW201350124A (zh) 用於治療、控制、改善或逆轉乾眼症之病狀之醫藥組合物及方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired